louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04953468: Expression of ANXA2 in the Extracellular Space in the Microenvironment of Periumoral Edema Promotes Glioma Invasion
Official title: Study on the Mechanism of the Expression of ANXA2 in the Extracellular Space in the Microenvironment of Periumoral Edema to Promote Glioma Invasion
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Glioma
Keywords: glioma
ANXA2 Expression
periatumoral edema zone
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-08
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients (aged 18-75 years) who underwent microsurgical resection of glioma in the Neurosurgery Department of Peking University Third Hospital between 2018 and 2020

Brief summary: The prognostic value of ANXA2 expression in tumor tissue and PTBE was analyzed, so as to seek new therapies to inhibit glioma invasion and improve the prognosis of glioma patients

Detailed description: The main reason for the poor prognosis of glioma is the invasion of tumor cells along the extracellular space (ECS) in the periatumoral edema zone (PTBE).Previous studies have shown that ANXA2 is highly expressed in glioma and promotes tumor growth and invasion, while its expression in the PTBE microenvironment of glioma and its mechanism of action on tumor invasion have not been reported.Previous study found that ANXA2 was overexpressed in gliomas and was associated with poor prognosis, and the low expression of ANXA2 significantly inhibited tumor invasion in vitro.Relevant studies have also confirmed that as an exocrine protein, it mainly plays a role in ECS, and it has previously been carried out on the tissue structure of ECS in tumor microenvironment.Therefore, investigators planned to study the mechanism of ANXA2 expression in PTBE microenvironment ECS on tumor invasion.This project aims to take glioma related issues as the research object and analyze tumor tissue and tumor tissue

Eligibility criteria: Inclusion Criteria:

* Patients who have undergone microneurosurgical resection of the tumor in our hospital and are pathologically confirmed to be supratentorial glioma;
* Preserving the remaining tissue samples of paired gliomas and PTBE for pathological examination;
* The patients agreed to be enrolled and signed the informed consent;
* The clinical data of the patients are complete and not lost;
* No serious complications occurred after surgery.

Exclusion Criteria:

* All glioma patients who did not meet the inclusion criteria

Primary outcomes:
measure: Overall survival
timeFrame: From the date of surgery to the date of death from any cause, assessed up to 18 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Yang Jun
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02079168: A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
Official title: A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Keloid
Keywords: Keloid
Cicatrix
Keloid prevention
Keloid revision/excision
Keloidectomy
Lead sponsor: RXi Pharmaceuticals, Corp.
Sponsor class: INDUSTRY
First posted: 2014-03-05
Enrollment: 16
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.


Eligibility criteria: Inclusion Criteria:

* Adults, 21-55 years of age.
* Two keloids of approximately similar size and anatomical location on the earlobe, neck, or torso.
* Keloids to be excised must have been present for \> 1 year.

Exclusion Criteria:

* Use of tobacco or nicotine-containing products
* Pregnant or lactating
* Post-menopausal or full hysterectomy

Primary outcomes:
measure: Reduction in the recurrence of a keloid after keloid excision
timeFrame: 6 months
Secondary outcomes:
measure: Safety of RXI-109
timeFrame: 6 months
Other outcomes:
Locations:
city: Miami
country: United States
state: Florida
city: St. Louis
country: United States
state: Missouri
city: San Cristobal
country: Dominican Republic
Study officials:
affiliation: RXi Pharmaceuticals
name: Pamela Pavco, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02293668: Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: poor responders
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2014-11-18
Enrollment: 95
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There are different controlled ovarian hyperstimulation protocols utilized in infertility patients. In this study, our aim is to specifically compare three protocols in poor responding infertility patients.


Eligibility criteria: Inclusion Criteria:

* Patients will be considered eligible if they are poor ovarian responders according to the Bologna criteria (Ferraretti et al., 2011).
* Two out of three of the following criteria are essential in order to classify a patient as poor ovarian responder:

  * advanced maternal age (≥40 years) or any other risk factor for poor ovarian response;
  * a poor ovarian response (≤3 oocytes with a conventional stimulation protocol); or
  * an abnormal ovarian reserve test (antral follicle count, \<7 follicles or anti-Mullerian hormone, \<1.1 ng/ml).

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: 8 weeks
Secondary outcomes:
measure: Number of oocytes retrieved
timeFrame: 4 weeks
measure: Number of transferable embryos
timeFrame: 4 weeks
measure: Biochemical pregnancy rate
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul University School of Medicine
Study officials:
References:
citation: Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.
Clinical trial NCT06168968: Multidisciplinary Approach to Reduce Cardiovascular Health Disparities
Official title: Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore RAcial Minority CommunitiEs (M-BRACE Trial)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Coronary Syndrome
Multi Vessel Coronary Artery Disease
Ischemic Stroke
Lead sponsor: LifeBridge Health
Sponsor class: OTHER
Collaborators: name: University of Maryland
First posted: 2023-12-13
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Two Cohorts (Cohort 1 = Secondary Prevention, Cohort 2 = Primary Prevention)

- See information about specific Cohorts

Brief summary: The goal of this observational study is to investigate the potential differences in thrombogenicity between black and white patients admitted with atherothrombotic events including acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke.

Participants will engage in laboratory testing and health outcome assessments.


Eligibility criteria: Inclusion Criteria:

* Patients ≥18 years of age admitted with ACS, AIS, or multi-vessel CAD
* Competent mental condition to provide informed consent and able to participate in follow-ups

Exclusion Criteria:

* Pregnant women
* Currently enrolled in an investigational drug or device trial
* Undergoing treatment for neoplastic, autoimmune, or connective tissue disease
* COVID-19 infection within 30 days of enrollment
* Known history of hepatitis or HIV
* Deemed unfit to participate according to the investigator
* Known history of drug abuse
* Known platelet count of \<100,000/mm3
* Hematocrit \< 25%

Primary outcomes:
measure: Differences in Platelet Fibrin Clot Formation (MA,mm)
timeFrame: Baseline
measure: Differences in Speed of Clot Formation (R, min)
timeFrame: Baseline
Secondary outcomes:
measure: Major Adverse Cardiovascular Events Post Index Hospitalization
timeFrame: 3 and 12 months post index hospitalization
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Sinai Hospital of Baltimore
state: Maryland
Study officials:
affiliation: LifeBridge Health
name: Jenna Brager, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04356768: Histological Analysis of Sacrococcygeal Pilonidal Sinus Specimens
Official title: Routine Histological Analysis of Sacrococcygeal Pilonidal Sinus Specimens, Retrospective Analysis of 1971 Resections.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pathology
Keywords: Pilonidal sinus
carcinoma
pathology
squamous cell carcinoma
phenol
Lead sponsor: Dr. Ersin Arslan Education and Training Hospital
Sponsor class: OTHER_GOV
First posted: 2020-04-22
Enrollment: 1971
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were operated on for pilonidal sinus between January 2016 and March 2020 at our hospital.

Brief summary: Minimally invasive techniques have been widely used routinely and reliably in the treatment of pilonidal sinus. In some of these methods, the cavity of sinus remains in the patient; this condition caused us to question the necessity of pathological examination. Except for prolonged duration of disease, elderly age, macroscopic suspicion, and recurrence; We think that routine pathological examination of the pilonidal sinus is unnecessary.

Detailed description: Pilonidal sinus is a benign disease. In the histopathological examination of pilonidal sinus specimens, malignancy can be detected rarely. Minimally invasive techniques have been widely used routinely and reliably in the treatment of pilonidal sinus. In some of these methods, the cavity of sinus remains in the patient; this condition caused us to question the necessity of pathological examination. The investigators aimed to discuss the pathological findings of patients who were operated for pilonidal sinus in our clinic in light of the literature. The fact that the rate of malignancy in the literature does not show parallelism with minimally invasive procedures that pathology samples are not taken and whose applications are increasing supports this prediction. Except for prolonged duration of disease, elderly age, macroscopic suspicion, and recurrence; the investigators think that routine pathological examination of the pilonidal sinus is unnecessary.

Eligibility criteria: Inclusion Criteria:

* sacrococcygeal pilonidal sinus

Exclusion Criteria:

* non-sacrococcygeal pilonidal sinus
* minimally invasive treatment without histopathological examination

Primary outcomes:
measure: Incidental cancer
timeFrame: 2 or 3 week
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Dr. Ersin Arslan Training and Resource Hospital
Study officials:
affiliation: Dr. Ersin Arslan Training and Resource Hospital
name: Ufuk Uylas, Specialist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03692468: A Brief Intervention for Chronic Pain in Primary Care
Official title: A Brief Intervention for Co-occurring Pain and Distress in Primary Care
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pain
Lead sponsor: Henry Ford Health System
Sponsor class: OTHER
First posted: 2018-10-02
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to investigate potential benefits of a behavioral intervention for co-occurring chronic pain and distress that is delivered in a primary care clinic.


Eligibility criteria: Inclusion Criteria:

* Chronic pain condition
* A current patient within the Henry Ford Health System Academic Internal Medicine Clinic in Detroit
* Has been within the Henry Ford Health System for at least 6 months

Exclusion Criteria:

* Current behavioral health treatment

Primary outcomes:
measure: Brief Pain Inventory
timeFrame: 5 weeks post-baseline
measure: Hospital Anxiety and Depression Scale
timeFrame: 5 weeks post-baseline
Secondary outcomes:
measure: Insomnia Severity Index
timeFrame: Administered at baseline, 5 weeks post-baseline, and 1 month and 6-month follow-ups
measure: Pain Catastrophizing Scale
timeFrame: Administered at baseline, 5 weeks post-baseline, and 1 month and 6-month follow-ups
measure: Satisfaction with Life Scale
timeFrame: Administered at baseline, 5 weeks post-baseline, and 1 month and 6-month follow-ups
measure: Health care utilization
timeFrame: Measured 6 months before and 6 months after study enrollment
Other outcomes:
measure: Chronic Pain Acceptance Questionnaire
timeFrame: Administered at baseline, 5 weeks post-baseline, and 1 month and 6-month follow-ups
measure: Mindful Attention Awareness Scale
timeFrame: Administered at baseline, 5 weeks post-baseline, and 1 month and 6-month follow-ups
measure: Montreal Cognitive Assessment
timeFrame: Administered at baseline
measure: Brief Medical Numbers Test
timeFrame: Administered at baseline
measure: Rapid Estimate of Adult Learning in Medicine
timeFrame: Administered at baseline
Locations:
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
Study officials:
References:
citation: Miller-Matero LR, Gavrilova L, Hecht LM, Autio K, Tobin ET, Braciszewski JM, Maye M, Felton JW, Ahmedani BK. A brief psychological intervention for chronic pain in primary care: Examining long-term effects from a pilot randomized clinical trial. Pain Pract. 2022 Jul;22(6):564-570. doi: 10.1111/papr.13134. Epub 2022 Jun 14.
citation: Miller-Matero LR, Hecht LM, Miller MK, Autio K, Pester BD, Tobin ET, Patel S, Braciszewski JM, Maye M, Ahmedani BK. A Brief Psychological Intervention for Chronic Pain in Primary Care: A Pilot Randomized Controlled Trial. Pain Med. 2021 Jul 25;22(7):1603-1611. doi: 10.1093/pm/pnaa444.
Clinical trial NCT01121068: Monthly Follow up of Interferon Gamma Releasing Assay (IGRA) Among Health-care Workers Treating Tuberculosis (TB) Patients
Official title: Monthly Follow up of Interferon Gamma Releasing Assay Among Health-care Workers Treating TB Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Keywords: IGRA
variability
Long-term variability of IGRA
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2010-05-12
Enrollment: 49
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Health care workers who are continuously exposed to TB patients

Brief summary: Interferon gamma releasing assay(IGRA) is useful to diagnose latent tuberculosis. However,IGRA responses could show within-subject variability. We wanted to determine long-term IGRA variability in health-care workers who continuously expose to tuberculosis patients.

Detailed description: IGRA will be performed monthly in health-care workers with continuous exposure to tuberculosis patients for 1 year.

Eligibility criteria: Inclusion Criteria:

* Health care workers who are continuously exposed to TB patients Age \> 20 years

Exclusion Criteria:

* Pregnant Active TB Use of immunosuppressants

Primary outcomes:
measure: Results of interferon-gamma releasing assay
timeFrame: monthly for 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine
Study officials:
affiliation: Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine
name: Jae-Joon Yim, MD
role: STUDY_CHAIR
References:
citation: Park JS, Lee JS, Kim MY, Lee CH, Yoon HI, Lee SM, Yoo CG, Kim YW, Han SK, Yim JJ. Monthly follow-ups of interferon-gamma release assays among health-care workers in contact with patients with TB. Chest. 2012 Dec;142(6):1461-1468. doi: 10.1378/chest.11-3299.
Clinical trial NCT00660868: Is Pentoxifylline Able to Improve Olfactory Sensitivity?
Official title: Agapurin Retard Used in Patients With Smell Disorder- A Post-marketing Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Olfaction Disorders
Keywords: smell
olfaction
olfactory sensitivity
smell loss
chemoreception
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2008-04-17
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: hyposmic or functionally anosmic patients TDI-score \<31; age: 18-50 years; odor threshold: better than 1; cause of smell loss: post traumatic, postinflammatory, idiopathic

Brief summary: Signal processing in the olfactory neuron could be influenced by inhibition of enzymes like phosphodiesterase. Pentoxifylline is a unspecific phosphodiesterase inhibitor. The hypothesis is that pentoxifylline could lead to increased sensitivity to odors.

Detailed description: Olfactory signal processing is conducted by a G-protein linked increase of intracellular concentration of adenosine 3´,5´-cyclic monophosphate (cAMP). In the cilia of olfactory sensory neurons (OSN) cAMP is degraded by phosphodiesterase 1C2 (PDE1C2). Inhibition of PDE1C2 could result in an increased response of OSN to chemical stimuli. Aim of the present prospective post-marketing surveillance study was to investigate the impact of pentoxifylline, an unspecific phosphodieasterase inhibitor, on olfactory function.

Eligibility criteria: Inclusion Criteria:

* hyposmic or functionally anosmic patients TDI-score \<31
* age: 18-50 years
* odor threshold: better than 1
* cause of smell loss: post traumatic, postinflammatory, idiopathic

Exclusion Criteria:

* normosmic patients,
* patients with contraindications for application of pentoxifylline
* patients that cannot give written agreement to the study
* patients under 18 years and over 50 years of age

Primary outcomes:
measure: TDI-score
timeFrame: at day 0 and follow up after 3 weeks
Secondary outcomes:
measure: odor threshold odor discrimination odor identification
timeFrame: at day 0 and at follow up after 3 weeks
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Zentrum für Riechen und Schmecken, Universitäts- HNO- Klinik Dresden
Study officials:
affiliation: Technische Universität Dresden
name: Volker Gudziol, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00818168: Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)
Official title: Remicade Safety Line (Ankylosing Spondylitis)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spondylitis, Ankylosing
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
Collaborators: name: Centocor, Inc.
First posted: 2009-01-07
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with ankylosing spondylitis.

Brief summary: This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness of tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).

Detailed description: This study population was chosen from a non-probability sample.

Eligibility criteria: Inclusion Criteria:

* Subjects with ankylosing spondylitis.

Exclusion Criteria:

* As per Summary of Product Characteristics (SmPC)

Primary outcomes:
measure: Number of Participants Who Had the Mendel Mantoux Test as the First Screening Test for Active or Latent Tuberculosis (TB) Before Starting Treatment
timeFrame: Baseline
measure: Number of Participants Who Had the Tine Test as the First Screening Test for Active or Latent Tuberculosis Before Starting Treatment
timeFrame: Baseline
measure: Number of Participants Who Had the In-vitro TB Test as the First Screening Test for Active or Latent Tuberculosis Before Starting
timeFrame: Baseline
measure: Number of Participants Who Had a Chest X-ray as Part of TB Screening for Active or Latent Tuberculosis Before Starting Treatment
timeFrame: Baseline
Secondary outcomes:
measure: Assessment of Disease Activity by Means of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at the Time of Enrollment and at the First Infusion
timeFrame: Baseline and time of first infusion
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00543868: MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Stomach Ulcer
Duodenal Ulcer
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2007-10-15
Enrollment: 462
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will determine how if MK0782 is safe and tolerable and to determine how often and the severity of stomach and small intestine ulcers develop following administration of MK0782 plus enteric coated aspirin, rofecoxib 25mg plus enteric coated aspirin, naproxen 500 mg puls enteric coated asprin vs placebo.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).


Eligibility criteria: Inclusion Criteria:

* Healthy male or non pregnant female
* 18 years of age or older (age at consent)
* Able to abstain from alcohol, tobacco, spicy foods, limit coffee
* Able to avoid strenuous activity
* Able to read and fill out a study diary

Exclusion Criteria:

* You have participated in an investigational drug study within 4 weeks of entering this study
* Your weight is not within a specific range for the study
* You have a history of GI problems like a gastric ulcer
* You have had gastric or intestinal surgery
* You have had abdominal or chest surgery
* You are currently abusing drugs or alcohol or have a history of abuse
* You have a history of psychiatric disorders
* You are a smoker or have smoked during the last year

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References: